329 related articles for article (PubMed ID: 26994951)
21. [Increased cardiovascular risk in HIV patients].
Wierema TK
Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
[TBL] [Abstract][Full Text] [Related]
22. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Grinspoon SK
Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
[TBL] [Abstract][Full Text] [Related]
23. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction.
Kline ER; Sutliff RL
J Investig Med; 2008 Jun; 56(5):752-69. PubMed ID: 18525451
[TBL] [Abstract][Full Text] [Related]
24. Venous and arterial thromboembolic complications associated with HIV infection and highly active antiretroviral therapy.
Auerbach E; Aboulafia DM
Semin Thromb Hemost; 2012 Nov; 38(8):830-8. PubMed ID: 23041980
[TBL] [Abstract][Full Text] [Related]
25. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.
Fisher SD; Miller TL; Lipshultz SE
Atherosclerosis; 2006 Mar; 185(1):1-11. PubMed ID: 16297390
[TBL] [Abstract][Full Text] [Related]
26. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.
Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P
AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019
[TBL] [Abstract][Full Text] [Related]
27. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
Barbaro G
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular disease associated with human immunodeficiency virus: a review.
Costa LA; Almeida AG
Rev Port Cardiol; 2015; 34(7-8):479-91. PubMed ID: 26162286
[TBL] [Abstract][Full Text] [Related]
29. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.
Neto MG; Zwirtes R; Brites C
Braz J Infect Dis; 2013; 17(6):691-700. PubMed ID: 23916459
[TBL] [Abstract][Full Text] [Related]
30. How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy.
Jaworowski A; Hearps AC; Angelovich TA; Hoy JF
Front Immunol; 2019; 10():1378. PubMed ID: 31275317
[TBL] [Abstract][Full Text] [Related]
31. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
Barbaro G
Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
[TBL] [Abstract][Full Text] [Related]
32. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection.
Titanji B; Gavegnano C; Hsue P; Schinazi R; Marconi VC
J Am Heart Assoc; 2020 Feb; 9(3):e014873. PubMed ID: 31973607
[No Abstract] [Full Text] [Related]
33. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies.
Bozkurt B
Cardiovasc Toxicol; 2004; 4(3):243-60. PubMed ID: 15470272
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome associated with HIV and highly active antiretroviral therapy.
Barbaro G; Iacobellis G
Curr Diab Rep; 2009 Feb; 9(1):37-42. PubMed ID: 19192423
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
Magen E; Elbirt D; Sthoeger Z
Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
[TBL] [Abstract][Full Text] [Related]
37. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era.
Ballocca F; Gili S; D'Ascenzo F; Marra WG; Cannillo M; Calcagno A; Bonora S; Flammer A; Coppola J; Moretti C; Gaita F
Prog Cardiovasc Dis; 2016; 58(5):565-76. PubMed ID: 26943980
[TBL] [Abstract][Full Text] [Related]
38. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
Cahn P; Leite O; Rosales A; Cabello R; Alvarez CA; Seas C; Carcamo C; Cure-Bolt N; L'Italien GP; Mantilla P; Deibis L; Zala C; Suffert T
Braz J Infect Dis; 2010; 14(2):158-66. PubMed ID: 20563442
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors.
da Cunha J; Ferreira Maselli LM; Treitinger A; Monteiro AM; Gidlund M; Maranhão RC; Spada C; Bydlowski SP
Clin Chem Lab Med; 2013 Feb; 51(2):371-8. PubMed ID: 23241595
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular effects of antiretroviral drugs: clinical review.
Filardi PP; Paolillo S; Marciano C; Iorio A; Losco T; Marsico F; Scala O; Ruggiero D; Ferraro S; Chiariello M
Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):238-44. PubMed ID: 19075633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
